Previous studies have shown that TP53 mutations predict the sensitivity of cancer cell lines to PLK1 inhibition [46,47,48,49,50,51], and that cells with a normal diploid karyotype are insensitive to PLK1 depletion [48,49,52]. This evidence concerns the gene TP53 and cancer.